trans fat

Trans fat refers to trans‑fatty acids (TFAs), a class of unsaturated fats that contain at least one double bond in the trans configuration. Unlike cis fats, which bend at double bonds and are common in natural unsaturated fats, trans fats have straighter structures that affect how enzymes in the body metabolize them. Trans fats occur in two principal forms: industrially produced trans fats and naturally occurring trans fats. Industrial trans fats are created by partial hydrogenation of vegetable oils, a chemical process that converts liquid oils into more solid fats to improve texture, shelf life, and stability of processed foods. Partially hydrogenated oils (PHOs) have historically been used in margarine, shortening, packaged baked goods, fried foods, and snack products because they were inexpensive and effective at resisting rancidity. However, this process also produces trans‑fatty acids that are harmful to human health. Naturally occurring trans fats are present in the fat of ruminant animals—cows, sheep, and goats—and are produced by microbial biohydrogenation in the rumen. These naturally occurring trans fats, such as vaccenic acid, typically comprise only a small fraction of total fat in dairy products and meat. However, regardless of origin, trans fats do not serve any essential biological function in humans. In contrast to essential fatty acids (like omega‑3 and omega‑6 fats), the body does not require trans fatty acids for growth, maintenance, or metabolic processes. Indeed, major health authorities have concluded that all trans fat intake increases the risk of cardiovascular disease and other chronic diseases. For example, World Health Organization guidance states that trans fat intake should be limited to less than 1% of total energy intake—equivalent to about 2.2 grams per day on a 2,000‑calorie diet—because of its harmful effects on lipid profiles, including raising LDL cholesterol and lowering HDL cholesterol. The US Food and Drug Administration determined that industrial trans fats from partially hydrogenated oils were no longer ‘generally recognized as safe’ (GRAS), leading to their effective removal from the US food supply beginning in 2018. Although trans fat intake in many nations has declined significantly, small amounts may still be present in processed foods due to labeling loopholes that allow products with <0.5 grams per serving to list 0 grams. Because the human body does not require trans fat and because even small amounts adversely affect cardiovascular risk markers, trans fats are considered a dietary liability rather than a nutrient to be consumed. Therefore, health professionals universally recommend minimizing trans fat intake, replacing them with healthier fats such as monounsaturated and polyunsaturated fats found in nuts, seeds, fish, and plant oils.

Unlike essential nutrients, trans fats do not fulfill beneficial physiological functions in the body. Instead, their intake is associated with harmful effects on lipid metabolism and cardiovascular health. The primary biological consequence of trans fat consumption is its profound effect on blood lipid profiles. Trans fatty acids raise low‑density lipoprotein (LDL) cholesterol, which contributes to atherosclerotic plaque formation, and lower high‑density lipoprotein (HDL) cholesterol, which normally helps remove cholesterol from artery walls. These alterations in lipid fractions are mechanistically linked to increased risk of coronary heart disease, as elevated LDL promotes cholesterol deposition in arterial walls, while reduced HDL impairs reverse cholesterol transport. Extensive epidemiological evidence shows a direct association between higher trans fat intake and increased risk of coronary heart disease (CHD) events and mortality. A pooled analysis from multiple cohorts reported that total trans fat intake is associated with increased all‑cause mortality and CHD mortality, even when controlling for confounding variables. In comparison with saturated fats, which also affect LDL cholesterol, trans fats have a stronger adverse effect on the LDL/HDL ratio. Replacement of trans fats with cis unsaturated fats (such as omega‑3 and omega‑6 fatty acids) is linked with significant reductions in CHD risk. In population studies, replacing 2% of energy from trans fats with unsaturated fats was associated with more than a 50% reduction in coronary artery disease risk, whereas replacing an equivalent energy from saturated fats yielded smaller risk reductions. Beyond lipid metabolism, trans fats may disrupt endothelial function and promote systemic inflammation. Trans fatty acids have been shown to increase markers of inflammation and endothelial dysfunction, such as C‑reactive protein and adhesion molecules, which are involved in the pathogenesis of atherosclerosis. Trans fats may also interfere with the metabolism of essential fatty acids, altering membrane phospholipid composition and impairing the generation of anti‑inflammatory eicosanoids. Some research suggests possible links between trans fat intake and other health outcomes, including insulin resistance and type 2 diabetes, although evidence is less consistent. A meta‑analysis of randomized controlled trials found that higher trans fat intake significantly increased total and LDL cholesterol and decreased HDL cholesterol, although effects on glucose homeostasis such as fasting glucose and insulin were not statistically significant. Nonetheless, the consistent detrimental impacts on cardiometabolic risk factors reinforce the conclusion that trans fats provide no health benefits and instead elevate disease risk. Consequently, authoritative health agencies emphasize reducing trans fat intake as a key public health priority for cardiovascular disease prevention. In summary, trans fats do not serve essential roles in human biochemistry; rather, they disrupt lipid and inflammatory pathways in ways that promote atherosclerosis and cardiometabolic disease. Reducing or eliminating trans fats from the diet is associated with improved lipid profiles, lower cardiovascular risk, and better overall metabolic health.

Trans fats are unique among dietary fats in that health authorities recommend minimizing intake rather than meeting a daily requirement. There is no Recommended Dietary Allowance (RDA) or Adequate Intake established for trans fats because they are not essential for physiological function. Instead, guidelines focus on limiting exposure due to well‑documented health risks. The World Health Organization advises that trans fat intake should be less than 1% of total energy intake to reduce the risk of cardiovascular disease. On a typical 2,000‑calorie diet, this translates to less than approximately 2.2 grams of trans fat per day. Many national dietary guidelines, including those from the US Dietary Guidelines for Americans, echo this advice by recommending that trans fat consumption be ‘‘as low as possible while consuming a nutritionally adequate diet.’’ The US Food and Drug Administration’s regulatory actions reflect this position: PHOs, the primary source of industrial trans fats in the food supply, were determined to be not generally recognized as safe (GRAS), effectively removing them from most food products. Because of labeling regulations, foods with less than 0.5 grams of trans fat per serving can be labeled as having ‘‘0 grams trans fat,’’ so consumers should check ingredient lists for ‘‘partially hydrogenated oils’’ to avoid hidden sources. Children, pregnant women, older adults, and individuals with existing cardiovascular disease all benefit from minimizing trans fat intake, as even small increments have been linked to adverse lipid changes and increased risk of heart disease. In summary, the optimal intake of trans fats is near zero, with authoritative guidance recommending less than 1% of total calories; no health benefit is associated with higher intakes, and even trace amounts contribute to increased disease risk.

Unlike essential nutrients, trans fats are not required by the human body, and there is no recognized deficiency state associated with low intake. The concept of ‘‘deficiency’’ does not apply to trans fats because they are not utilized in critical biochemical pathways or structural functions. Trans fats do not have a designated role in cell signaling, membrane structure, or energy metabolism in a way that would make their absence detrimental. Instead, the absence or minimal presence of trans fats is considered indicative of a healthier dietary pattern. Public health guidance consistently emphasizes the elimination or near‑elimination of trans fats from the diet, particularly industrial trans fats derived from partially hydrogenated oils, due to their link to increased LDL cholesterol, reduced HDL cholesterol, and elevated risk of atherosclerotic cardiovascular disease. Therefore, there are no clinical signs, symptoms, or laboratory markers associated with inadequate intake of trans fats. At‑risk populations for adverse effects from trans fats are those with higher intake levels, such as individuals who frequently consume processed or fried foods prepared with partially hydrogenated oils. Reductions in trans fat consumption are associated with improved lipid profiles, including lower LDL and higher HDL cholesterol levels, and correspondingly lower rates of coronary heart disease. In summary, ‘‘deficiency’’ of trans fat is not a concept in clinical nutrition, and minimizing intake is universally recommended rather than meeting a required threshold.

Trans fats are found in both processed foods and in small amounts in some animal products. The most significant sources historically have been foods made with partially hydrogenated oils, which are industrially produced to extend shelf life and enhance texture. While many countries have banned or limited industrial trans fats, trace amounts may still appear in processed foods due to regulatory labeling rules that allow products with <0.5 grams per serving to claim ‘‘0 grams’’ of trans fat on the label. Common food sources include baked goods such as cakes, cookies, pies, and frostings made with shortening or margarine, fried items such as French fries, doughnuts, and fried chicken, and snack foods like crackers and microwave popcorn. Some packaged breakfast foods, frozen meals, and non‑dairy creamers have historically contributed to trans fat consumption when formulated with partially hydrogenated oils. Although industrial trans fats have been largely removed from many food supplies, naturally occurring trans fats are present at low levels (usually a few percent of total fat) in dairy products such as whole milk, butter, cheese, yogurt, and in meat from ruminant animals due to microbial biohydrogenation in the rumen. These naturally occurring trans fats include specific isomers like vaccenic acid, which differ slightly in structure from industrial trans fats, though health authorities generally consider all trans fats potentially harmful at higher intakes. When evaluating food labels, consumers can identify potential trans fat content by checking for ‘‘partially hydrogenated oils’’ in ingredient lists even when the nutrition panel lists ‘‘0 g trans fat,’’ because regulatory rounding rules permit small amounts to be hidden. Minimizing intake of processed and fried foods and choosing whole, minimally processed foods with healthier fats—such as monounsaturated and polyunsaturated fats from nuts, seeds, fish, avocados, and plant oils—supports cardiovascular health and reduces overall trans fat exposure.

Trans fats, like other dietary fats, are absorbed through the small intestine. After ingestion, fats are emulsified by bile salts and hydrolyzed by pancreatic lipases into free fatty acids and monoacylglycerols, which are absorbed into enterocytes. Within enterocytes, these components are re‑esterified into triglycerides and incorporated into chylomicrons for transport through the lymphatic system into systemic circulation. Because trans fats structurally resemble other unsaturated fats, their absorption efficiency is similar to that of cis unsaturated fatty acids. However, once incorporated into circulating lipoproteins, trans fats influence lipid metabolism differently, tending to raise LDL cholesterol and lower HDL cholesterol. Factors that influence absorption of fats in general—such as the presence of dietary fiber, bile salt availability, and overall fat intake—also affect trans fat absorption. High‑fat meals, especially those containing processed fats, stimulate chylomicron formation and delivery of fatty acids to peripheral tissues. Although there is no need to ‘‘enhance’’ absorption of trans fats (given their harmful effects), understanding how fats are processed biologically underscores why dietary patterns rich in healthier fats are preferable. In contrast to essential fatty acids, which may have specific transport and metabolic fates linked to cell signaling and membrane function, trans fats primarily serve as energy sources and perturb normal lipid metabolism, contributing to adverse cardiovascular effects.

Because trans fats are not essential and have no recognized health benefits, there is no rationale for trans fat supplements. No dietary supplement form of trans fats is recommended by health professionals or regulatory agencies. In fact, supplementing with trans fats would be counterproductive and harmful, as trans fats increase LDL cholesterol, lower HDL cholesterol, and elevate the risk of coronary heart disease and other cardiometabolic conditions. Instead of focusing on adding trans fats to the diet, health guidance emphasizes replacing trans fats and saturated fats with healthier fats, such as monounsaturated and polyunsaturated fats from sources like olive oil, nuts, seeds, and fish. Professional organizations, including the American Heart Association and World Health Organization, advocate for near‑zero intake of industrial trans fats and emphasize whole‑food dietary patterns. There are no clinical indications, dosing regimens, or therapeutic contexts in which trans fat supplementation would be appropriate. Therefore, ‘‘trans fat supplements’’ are neither marketed nor supported by evidence for any health benefit. Consumers seeking to improve lipid profiles and cardiovascular health should instead consider evidence‑based supplements with proven benefits, such as omega‑3 fatty acids, under the guidance of a healthcare provider.

There is no established tolerable upper intake level for trans fats because any intake above trace amounts is associated with increased disease risk. Epidemiological and clinical evidence shows that trans fat intake adversely affects lipid profiles and increases the risk of cardiovascular disease even at relatively low levels, which is why authorities recommend minimizing intake. The World Health Organization’s guideline of less than 1% of total energy intake (approximately <2.2 grams per day on a 2,000‑calorie diet) reflects evidence that even small amounts raise LDL cholesterol and lower HDL cholesterol, contributing to atherosclerosis and CHD risk. Industrial trans fats have been linked to increased all‑cause mortality, coronary heart disease mortality, and total coronary events in cohort studies. Because harm increases with intake and no beneficial effects exist, the ‘‘upper limit’’ concept is replaced with a ‘‘as low as possible’’ approach. Regulatory actions such as bans on partially hydrogenated oils in the United States and other countries are rooted in the understanding that industrial trans fats are not safe at typical consumption levels and contribute to substantial public health burdens. Thus, trans fat avoidance rather than threshold‑guided intake is the paradigm used by health organizations.

There are no specific medications known to interact directly with trans fats at the molecular level. However, trans fat intake influences lipid profiles and may modulate the effectiveness of lipid‑lowering drugs such as statins. Because trans fats raise LDL cholesterol and lower HDL cholesterol, they can counteract the benefits of medications prescribed to improve lipid profiles. Patients taking statins or other lipid‑modifying therapies should minimize trans fat intake to enhance therapeutic outcomes. High trans fat diets may also contribute to systemic inflammation and endothelial dysfunction, potentially increasing cardiovascular risk independent of medication effects. There is no evidence that trans fats directly interfere with drug metabolism enzymes such as cytochrome P450 pathways, but their influence on cardiovascular risk factors can affect clinical endpoints targeted by cardiovascular drugs. Therefore, counseling on dietary fat quality is an important adjunct to pharmacotherapy for dyslipidemia.